350 related articles for article (PubMed ID: 25749422)
1. WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation.
Liu H; Chen W; Liang C; Chen BW; Zhi X; Zhang S; Zheng X; Bai X; Liang T
Cancer Lett; 2015 Jun; 361(2):218-25. PubMed ID: 25749422
[TBL] [Abstract][Full Text] [Related]
2. WP1130 attenuates cisplatin resistance by decreasing P53 expression in non-small cell lung carcinomas.
Wang X; Bao Y; Dong Z; Chen Q; Guo H; Ziang C; Shao J
Oncotarget; 2017 Jul; 8(30):49033-49043. PubMed ID: 28446729
[TBL] [Abstract][Full Text] [Related]
3. miR-26b enhances the sensitivity of hepatocellular carcinoma to Doxorubicin via USP9X-dependent degradation of p53 and regulation of autophagy.
Chen E; Li E; Liu H; Zhou Y; Wen L; Wang J; Wang Y; Ye L; Liang T
Int J Biol Sci; 2021; 17(3):781-795. PubMed ID: 33767588
[TBL] [Abstract][Full Text] [Related]
4. Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis.
Kapuria V; Peterson LF; Fang D; Bornmann WG; Talpaz M; Donato NJ
Cancer Res; 2010 Nov; 70(22):9265-76. PubMed ID: 21045142
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of Ubiquitin Carboxyl-Terminal Hydrolase L1 (UCHL1) Mediates the Reversal Effect of Verapamil on Chemo-Resistance to Adriamycin of Hepatocellular Carcinoma.
Yang G; Fan G; Zhang T; Ma K; Huang J; Liu M; Teng X; Xu K; Fan P; Cheng D
Med Sci Monit; 2018 Apr; 24():2072-2082. PubMed ID: 29627846
[TBL] [Abstract][Full Text] [Related]
6. ARK5 promotes doxorubicin resistance in hepatocellular carcinoma via epithelial-mesenchymal transition.
Xu T; Zhang J; Chen W; Pan S; Zhi X; Wen L; Zhou Y; Chen BW; Qiu J; Zhang Y; Yang Q; Feng X; Bai X; Liang T
Cancer Lett; 2016 Jul; 377(2):140-8. PubMed ID: 27126361
[TBL] [Abstract][Full Text] [Related]
7. Dihydroartemisinin Sensitizes Mutant p53 (R248Q)-Expressing Hepatocellular Carcinoma Cells to Doxorubicin by Inhibiting P-gp Expression.
Yang Y; He J; Chen J; Lin L; Liu Y; Zhou C; Su Y; Wei H
Biomed Res Int; 2019; 2019():8207056. PubMed ID: 31976328
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU.
Li X; Yu J; Brock MV; Tao Q; Herman JG; Liang P; Guo M
Oncotarget; 2015 May; 6(13):11547-60. PubMed ID: 25909168
[TBL] [Abstract][Full Text] [Related]
9. Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism.
Giovannini C; Gramantieri L; Chieco P; Minguzzi M; Lago F; Pianetti S; Ramazzotti E; Marcu KB; Bolondi L
J Hepatol; 2009 May; 50(5):969-79. PubMed ID: 19304334
[TBL] [Abstract][Full Text] [Related]
10. SIRT7 regulates hepatocellular carcinoma response to therapy by altering the p53-dependent cell death pathway.
Zhao J; Wozniak A; Adams A; Cox J; Vittal A; Voss J; Bridges B; Weinman SA; Li Z
J Exp Clin Cancer Res; 2019 Jun; 38(1):252. PubMed ID: 31196136
[TBL] [Abstract][Full Text] [Related]
11. MiR-34a overexpression enhances the inhibitory effect of doxorubicin on HepG2 cells.
Zheng SZ; Sun P; Wang JP; Liu Y; Gong W; Liu J
World J Gastroenterol; 2019 Jun; 25(22):2752-2762. PubMed ID: 31235998
[TBL] [Abstract][Full Text] [Related]
12. Hepatocellular carcinoma and chemotherapy: the role of p53.
Brito AF; Abrantes AM; Pinto-Costa C; Gomes AR; Mamede AC; Casalta-Lopes J; Gonçalves AC; Sarmento-Ribeiro AB; Tralhão JG; Botelho MF
Chemotherapy; 2012; 58(5):381-6. PubMed ID: 23257706
[TBL] [Abstract][Full Text] [Related]
13. Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the β-catenin/TCF complex association via FOXO3a activation.
Zhou Y; Liang C; Xue F; Chen W; Zhi X; Feng X; Bai X; Liang T
Oncotarget; 2015 Apr; 6(12):10350-65. PubMed ID: 25871400
[TBL] [Abstract][Full Text] [Related]
14. Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways.
Zheng T; Wang J; Song X; Meng X; Pan S; Jiang H; Liu L
J Cancer Res Clin Oncol; 2010 Oct; 136(10):1597-604. PubMed ID: 20174822
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-215 is upregulated by treatment with Adriamycin and leads to the chemoresistance of hepatocellular carcinoma cells and tissues.
Wang L; Wang YM; Xu S; Wang WG; Chen Y; Mao JY; Tian BL
Mol Med Rep; 2015 Oct; 12(4):5274-80. PubMed ID: 26135967
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of HURP inhibits the proliferation of hepacellular carcinoma cells via downregulation of gankyrin and accumulation of p53.
Kuo TC; Chang PY; Huang SF; Chou CK; Chao CC
Biochem Pharmacol; 2012 Mar; 83(6):758-68. PubMed ID: 22230478
[TBL] [Abstract][Full Text] [Related]
17. Variant 1 of KIAA0101, overexpressed in hepatocellular carcinoma, prevents doxorubicin-induced apoptosis by inhibiting p53 activation.
Liu L; Chen X; Xie S; Zhang C; Qiu Z; Zhu F
Hepatology; 2012 Nov; 56(5):1760-9. PubMed ID: 22576474
[TBL] [Abstract][Full Text] [Related]
18. Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line.
Chan KT; Lung ML
Cancer Chemother Pharmacol; 2004 Jun; 53(6):519-26. PubMed ID: 15004724
[TBL] [Abstract][Full Text] [Related]
19. A novel all-trans retinoic acid derivative 4-amino‑2‑trifluoromethyl-phenyl retinate inhibits the proliferation of human hepatocellular carcinoma HepG2 cells by inducing G0/G1 cell cycle arrest and apoptosis via upregulation of p53 and ASPP1 and downregulation of iASPP.
Liu H; Chen F; Zhang L; Zhou Q; Gui S; Wang Y
Oncol Rep; 2016 Jul; 36(1):333-41. PubMed ID: 27177208
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of deubiquitinases primes glioblastoma cells to apoptosis in vitro and in vivo.
Karpel-Massler G; Banu MA; Shu C; Halatsch ME; Westhoff MA; Bruce JN; Canoll P; Siegelin MD
Oncotarget; 2016 Mar; 7(11):12791-805. PubMed ID: 26872380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
